Panic Attack Treatment Market By Panic Attacks Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Panic Attack Treatment Market
Panic Attack Treatment Market: By Panic Attacks Type (Generalized Anxiety Disorder, Obsessive-Compulsive Disorder (OCD) and Others); By Drug (SSRI, SNRI and BZD) & By Region - Forecast (2016-2021)
Report Code : HCR 0258
Updated Date: 14 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Panic attacks are associated with sudden surge of overwhelming anxiety and fear. Globally, development of advance technology for treatment of panic attacks, rise in the incidences of panic attacks, owing to stressful life, sedentary lifestyle, and increasing awareness about panic attacks and its negative affect the quality of life. In addition, increase in adoption of panic attack treatment in emerging economies such as China, India and others, will create new opportunities for panic attack treatment market. However, side effects of medications such as dry mouth, nauseacould, and habit forming nature, and poor diagnosis rate to detect anxiety disorders are the key restraints for panic attack treatment market.

This report identifies the global panic attack treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to panic attack treatment market.
 
Panic Attack Treatment Market

Geographically, North America dominated the panic attack treatment market, owing to rise in incidence of panic attacks, and prevalence of awareness among people related to anxiety disorders. Asia Pacific is projected to have the fastest growth, owing to rapidly increasing stress due to changing lifestyle and modernising healthcare infrastructure in developing nations such as China, and India in this region. Among all the drugs, Selective Serotonin Reuptake Inhibitor (SSRI) has the highest market share in panic attack treatment market.

This report segments panic attack treatment market on the basis of panic attacks type, drug, and regional market as follows:
  • Panic Attack Treatment Market, By Panic Attacks Type: Generalized Anxiety Disorder, Obsessive-Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder, and Other Special Phobias
  • Panic Attack Treatment Market, By Drug: Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin Norepinephrine Reuptake Inhibitor (SNRI), and Benzodiazepines (BZD)
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the panic attack treatment market. Some of the major companies’ profiles in detail are as follows:
  • GlaxoSmithKline Pharmaceuticals Limited
  • F. Hoffmann-La Roche
  • Actavis Pharmaceutical Company
  • Noven Pharmaceuticals, Inc.
  • Recordati Rare Diseases
1. Panic Attack Treatment Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Panic Attack Treatment Market– Market Forces
   4.1. Drivers
      4.1.1. Development of advance technology for treatment of panic attacks
      4.1.2. Rise in the incidences of panic attacks, owing to stressful life, sedentary lifestyle
      4.1.3. Increasing awareness about panic attacks and its negative affect the quality of life
   4.2. Restraints
      4.2.1. Side effects of medications such as dry mouth, nauseacould, and habit forming nature
      4.2.2. Poor diagnosis rate to detect anxiety disorders
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Panic Attack Treatment Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Panic Attack Treatment Market, By Panic Attacks Type
   6.1. Generalized Anxiety Disorder
   6.2. Obsessive-Compulsive Disorder (OCD)
   6.3. Posttraumatic Stress Disorder (PTSD)
   6.4. Social Anxiety Disorder
   6.5. Other Special Phobias
7. Panic Attack Treatment Market, By Drug
   7.1. Selective Serotonin Reuptake Inhibitor (SSRI)
   7.2. Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
   7.3. Benzodiazepines (BZD)
8. Panic Attack Treatment Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Panic Attack Treatment – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
      9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. GlaxoSmithKline Pharmaceuticals Limited
   10.2. F. Hoffmann-La Roche
   10.3. Actavis Pharmaceutical Company
   10.4. Noven Pharmaceuticals, Inc.
   10.5. Recordati Rare Diseases
   10.6. Shionogi and Company
   10.7. Abbott Laboratories
   10.8. Sumitomo Dainippon Pharma
   10.9. Pfizer,Inc.
   10.10. Bristol-Myers Squibb
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll